Goldman Sachs’s ImmunityBio IBRX Stock Holding History

Goldman Sachs’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-69,300	Closed	-$438K	–	5947
2024 Q2	$438K	Buy	+69,300	New	+$457K	﹤0.01%	4901
2024 Q1	–	Sell	-11,500	Closed	-$57.7K	–	5707
2023 Q4	$57.7K	Buy	+11,500	New	+$36.1K	﹤0.01%	5358
2016 Q1	–	Sell	-63,300	Closed	-$1.1M	–	7176
2015 Q4	$1.1M	Buy	+63,300	New	+$939K	﹤0.01%	4204

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Goldman Sachs's IBRX Position: Q1 2026 in Review

Goldman Sachs reduced its ImmunityBio (IBRX) stake by 47% in Q1 2026, selling an estimated $20M and leaving 3,237,078 shares worth $24.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2222.

Goldman Sachs first reported a position in IBRX in Q4 2015 and has held it in 38 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Goldman Sachs held 3,237,078 shares of ImmunityBio worth $24.8M as of Q1 2026.
Goldman Sachs sold 2,915,606 ImmunityBio shares in Q1 2026, an estimated $20M.
ImmunityBio made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2222 holding.
Goldman Sachs first reported a position in ImmunityBio in Q4 2015 and has held it in 38 quarters since.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.